Revance Therapeutics Inc. (RVNC)

23.95
0.32 1.32
NASDAQ : Health Technology
Prev Close 24.27
Open 24.16
Day Low/High 23.84 / 24.79
52 Wk Low/High 22.25 / 37.45
Volume 160.74K
Avg Volume 243.40K
Exchange NASDAQ
Shares Outstanding 36.94M
Market Cap 914.95M
EPS -4.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Revance To Participate In The Cantor Fitzgerald 2018 Global Healthcare Conference

Revance To Participate In The Cantor Fitzgerald 2018 Global Healthcare Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Cantor Fitzgerald 2018 Global Healthcare...

Revance Receives Great Place To Work Certification

Revance Receives Great Place To Work Certification

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company was certified as a great workplace this month by the independent...

Notable Friday Option Activity: RVNC, MPWR, FIZZ

Notable Friday Option Activity: RVNC, MPWR, FIZZ

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Revance Therapeutics Inc , where a total of 1,134 contracts have traded so far, representing approximately 113,400 underlying shares. That amounts to about 61.8% of RVNC's average daily trading volume over the past month of 183,390 shares.

Revance Therapeutics Is Now Oversold (RVNC)

Revance Therapeutics Is Now Oversold (RVNC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Allergan CEO: Botox Is in a Very Strong Position, Despite Growing Competition

Allergan CEO: Botox Is in a Very Strong Position, Despite Growing Competition

The entrance of more competition for Botox Cosmetic could expand the market, the drugmaker's top executive says at the Wells Fargo Healthcare Conference in Boston.

Revance Releases Second Quarter 2018 Results

Revance Releases Second Quarter 2018 Results

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced results for the second quarter ended June 30, 2018.

Revance Therapeutics To Release Second Quarter 2018 Financial Results On Thursday, August 2, 2018

Revance Therapeutics To Release Second Quarter 2018 Financial Results On Thursday, August 2, 2018

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will release second quarter 2018 financial results on Thursday, August...

Revance Doses First Patient In ASPEN Phase 3 Clinical Program Of RT002 Injectable For The Treatment Of Cervical Dystonia

Revance Doses First Patient In ASPEN Phase 3 Clinical Program Of RT002 Injectable For The Treatment Of Cervical Dystonia

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced initiation of patient dosing in the company's ASPEN Phase 3 clinical program for its...

Revance To Participate In The JMP Securities Life Sciences Conference 2018

Revance To Participate In The JMP Securities Life Sciences Conference 2018

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the JMP Securities Life Sciences Conference 2018 in...

Revance To Participate In Upcoming Investor Conferences

Revance To Participate In Upcoming Investor Conferences

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor conferences.

Revance Announces Departure Of Chief Financial Officer

Revance Announces Departure Of Chief Financial Officer

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that Lauren Silvernail has resigned as Revance's Chief Financial Officer and Chief...

Revance Announces Publication Of Positive 24-Week Duration Of Effect Results From Cervical Dystonia Phase 2 Trial In Movement Disorders Clinical Practice

Revance Announces Publication Of Positive 24-Week Duration Of Effect Results From Cervical Dystonia Phase 2 Trial In Movement Disorders Clinical Practice

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that results of a Phase 2 study of DaxibotulinumtoxinA for Injection (RT002) to treat...

Allergan's Meury Talks Market Expansion in Aesthetics

Allergan's Meury Talks Market Expansion in Aesthetics

The chief commercial officer's appearance at a Bank of America healthcare conference came a day after Allergan competitor Evolus said it had received a complete response letter regarding its application for Botox rival DWP-450.

Revance To Participate In The UBS Global Healthcare Conference

Revance To Participate In The UBS Global Healthcare Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the Company will participate in the UBS Global Healthcare Conference in...

Revance Therapeutics Announces Two Recent Additions To Its Management Team

Revance Therapeutics Announces Two Recent Additions To Its Management Team

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the expansion of its management team with the appointments of Conor Gallagher, Ph.

Revance Releases First Quarter 2018 Results

Revance Releases First Quarter 2018 Results

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced results for the first quarter ended March 31, 2018.

Revance Therapeutics Expands Leadership Team, Appointing Caryn McDowell As SVP, General Counsel & Corporate Secretary

Revance Therapeutics Expands Leadership Team, Appointing Caryn McDowell As SVP, General Counsel & Corporate Secretary

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the expansion of its executive leadership team with the appointment of Caryn...

Jim's Daily Rundown

Jim discusses the trade tariff deadline extension, Emerson Electric's earnings, last night's interview with Allergan CEO Brent Saunders, Goldman Sachs, 3M and more!

Revance Therapeutics Took the Least Resistance Path, Turned Lower

Revance Therapeutics Took the Least Resistance Path, Turned Lower

Let's see what else has weakened.

Allergan First Quarter Earnings

The market is looking past the positive results as the commentary surrounding the breakup overshadowed the earnings.

Pivotal SAKURA Phase 3 Clinical Data To Be Featured In Oral And Poster Presentations At The Aesthetic Meeting 2018

Pivotal SAKURA Phase 3 Clinical Data To Be Featured In Oral And Poster Presentations At The Aesthetic Meeting 2018

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced oral and ePoster presentations of clinical data from the company's two pivotal SAKURA...

Revance Therapeutics To Release First Quarter 2018 Financial Results On Tuesday, May 8, 2018

Revance Therapeutics To Release First Quarter 2018 Financial Results On Tuesday, May 8, 2018

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will release first quarter 2018 financial results on Tuesday, May 8,...

Revance Investor Day Highlights New Neuroscience Indications In Development

Revance Investor Day Highlights New Neuroscience Indications In Development

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, is holding its first Investor Day in New York City today.

Revance Therapeutics Stock Looks Ready for New Gains

Revance Therapeutics Stock Looks Ready for New Gains

I don't understand the fundamentals but I find the chart interesting.

Technology Is Fueling Gains: Cramer's 'Mad Money' Recap (Wednesday 4/18/18)

Technology Is Fueling Gains: Cramer's 'Mad Money' Recap (Wednesday 4/18/18)

How do you get a stock moving? Jim Cramer says the answer is to invest in technology.

Revance Therapeutics: Cramer's Top Takeaways

Revance Therapeutics: Cramer's Top Takeaways

Dan Browne, co-founder, president and CEO of Revance Therapeutics, tells Jim Cramer his company is developing an alternative to Botox.

Biosimilar Pipeline Among Areas of Shareholder Focus at Mylan's Investor Day

Biosimilar Pipeline Among Areas of Shareholder Focus at Mylan's Investor Day

The pharmaceutical firm will conduct its investor day in New York City on April 11.

TheStreet Quant Rating: D (Sell)